According to Morningstar’s quantitative equity report dated March 27, 2026, AJJ Medtech Holdings Ltd (SGX: 584) received a 4-star quantitative rating. The report shows a Price/Fair Value ratio of 0.68, implying that the stock is trading at about a 32% discount to Morningstar’s quantitative fair value estimate.
Key points from the report include:
Company: AJJ Medtech Holdings Ltd
Ticker: SGX: 584
Morningstar quantitative rating: 4 stars
Price/Fair Value: 0.68
Implied discount to fair value: about 32%
3-year revenue growth: 75%
FY2025 revenue: about SGD 3.19 million
FY2025 net income: about -SGD 2.93 million
Economic moat: None
Uncertainty: Very High
Sector: Healthcare
Industry: Medical Devices
Morningstar notes that AJJ Medtech’s 3-year revenue growth of 75% places it in the top 10% versus global peers, which is a positive factor in its quantitative fair value assessment. At the same time, the report highlights that the company remains loss-making, has no economic moat, and carries a Very High uncertainty rating.
Frequently Asked Questions
Q: What is Morningstar’s latest core view on AJJ Medtech?
A: Morningstar assigns AJJ Medtech a 4-star quantitative rating and estimates that the stock is trading at about a 32% discount to fair value.
Q: What is the main positive factor mentioned in the report?
A: The main positive factor is AJJ Medtech’s 3-year revenue growth of 75%, which ranks in the top 10% globally among peers.
Q: What are the main risks highlighted in the report?
A: The main risks include continued losses, no economic moat, and a Very High uncertainty rating.
Comments